Mithra Pharmaceuticals

Mithra Pharmaceuticals SA. Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.
  • TickerMITRA
  • ISINBE0974283153
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryBelgium
Lenny Van Steenhuyse ...
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

Morning Note: DSM NA, IVA FP, MITRA BB, QRF BB

DSM: 2Q EBITDA -8%, Nutrition demonstrating resilience Inventiva: A top contender in the NASH race Mithra: Myring – extended shelf life in EU Qrf: 1HY20; COVID-19 deal in line with market practice

Alan Vandenberghe ...
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Michiel Declercq
  • Sandra Cauwenberghs

Morning Note: ACKB BB, CYAD BB, GVNV NA, MITRA BB

Ackermans: Commits $ 15m to Indian HealthQuad II Celyad: CYAD-211 IND clearance gives GO for phI start GrandVision: EU could ask EL to sell stores Mithra: Myring agreement in Mexico with Megalabs

Lenny Van Steenhuyse ...
  • Sandra Cauwenberghs
  • Thomas Couvreur

Morning Note: ENX FP, MITRA BB

Euronext: June market volumes Mithra: Myring agreement in France, Poland, UK

Guy Sips ...
  • Jason Kalamboussis
  • Michiel Declercq
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

Morning Note: BAR BB, CPINV BB, GIMB BB, MITRA BB, NN NA, SOLB BB, XIOR BB

Barco: Share split by a factor 7 as of 1 July CP Invest: Post ABB LTV in shape for further growth Gimv: Information on stock dividend Mithra: Estelle NDA submission accepted by FDA NN Group: CMD targets: ambitious OCG, no disposals in view Solvay: Revenue down 20% in April-May, € 1.5bn impairment Xior: Surprising resistant occupancy ramp-up

Bart Cuypers ...
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Wido Jongman

Morning Note: HEIJM NA, INGA NA, MITRA BB, XIOR BB

Heijmans: € 70m Rotterdam home development win ING: CRO becomes New CEO, no surprise, just in time Mithra: Capital increase of € 65m to support Donesta Xior: Sizable transaction with LIFE

Mithra Pharmaceuticals: 1 director sold

A director at Mithra Pharmaceuticals sold 560,200 shares at 25.572EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The name...

Lenny Van Steenhuyse ...
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

Morning Note: DSM NA, IVA FP, MITRA BB, QRF BB

DSM: 2Q EBITDA -8%, Nutrition demonstrating resilience Inventiva: A top contender in the NASH race Mithra: Myring – extended shelf life in EU Qrf: 1HY20; COVID-19 deal in line with market practice

Alan Vandenberghe ...
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Michiel Declercq
  • Sandra Cauwenberghs

Morning Note: ACKB BB, CYAD BB, GVNV NA, MITRA BB

Ackermans: Commits $ 15m to Indian HealthQuad II Celyad: CYAD-211 IND clearance gives GO for phI start GrandVision: EU could ask EL to sell stores Mithra: Myring agreement in Mexico with Megalabs

Lenny Van Steenhuyse ...
  • Sandra Cauwenberghs
  • Thomas Couvreur

Morning Note: ENX FP, MITRA BB

Euronext: June market volumes Mithra: Myring agreement in France, Poland, UK

Guy Sips ...
  • Jason Kalamboussis
  • Michiel Declercq
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

Morning Note: BAR BB, CPINV BB, GIMB BB, MITRA BB, NN NA, SOLB BB, XIOR BB

Barco: Share split by a factor 7 as of 1 July CP Invest: Post ABB LTV in shape for further growth Gimv: Information on stock dividend Mithra: Estelle NDA submission accepted by FDA NN Group: CMD targets: ambitious OCG, no disposals in view Solvay: Revenue down 20% in April-May, € 1.5bn impairment Xior: Surprising resistant occupancy ramp-up

Bart Cuypers ...
  • Jason Kalamboussis
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Wido Jongman

Morning Note: HEIJM NA, INGA NA, MITRA BB, XIOR BB

Heijmans: € 70m Rotterdam home development win ING: CRO becomes New CEO, no surprise, just in time Mithra: Capital increase of € 65m to support Donesta Xior: Sizable transaction with LIFE

MITHRA SA sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of MITHRA SA (BE), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 2 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date April 21, 2020, the closing price was EUR 21.20 and its target price was estimated at EUR 15.23.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch